Search
forLearn
5 / 801 resultslearn APISCALP™
learn procapil
learn Carpronium chloride hydrate
learn panthenyl ethyl ether
Research
5 / 1000+ results
research Cicatricial pattern hair loss is not a variant of lichen planopilaris
Cicatricial pattern hair loss is likely advanced common baldness, not a type of lichen planopilaris.
research Diffuse scarring alopecia in a female pattern hair loss distribution
Scarring hair loss found in female pattern; biopsy needed for diagnosis.
research Rapidly progressive diffuse fibrosing alopecia
These hair loss conditions might be part of a spectrum, not separate issues.
research Female Androgenetic Alopecia: An Update on Diagnosis and Management
FAGA diagnosis uses blood tests and trichoscopy, with treatments like topical minoxidil, oral anti-androgens, and hormone-modulating drugs.
research Common causes of hair loss – clinical manifestations, trichoscopy and therapy
The document concludes that understanding and treating hair loss requires recognizing its various types and using appropriate diagnostic tools and treatments.
Community Join
5 / 1000+ resultscommunity Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community Pelage to present PP405 Phase 2a clinical trial full results at an upcoming medical meeting - CMO Christina Weng says
Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.
community Pelage Pharmaceutical Raises 120 million to continue PP405 Research. Link inside.
Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.
community Approve PP405 quickly you coward
Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.
community PTD-DBM Update: Q&A With Dr. Kang-Yell Choi
PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.